GeneSystem Co

GeneSystem Co Net Debt per Share

The Net Debt per Share of GeneSystem Co (363250.KQ) as of Oct 30, 2026 is 284.06 KRW. In the previous year, Net Debt per Share was -658.01 KRW — a change of -143.17% (higher).

Net Debt per Share

284.06KRW

YoY

-143.17%

Last updated:

Net Debt per Share of GeneSystem Co is 2025 284.06 KRW. Net Debt per Share of GeneSystem Co was 2024 -658.01 KRW. It decreases by -143.17% higher compared to the previous year.

The GeneSystem Co Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
49.31 KRW
Jan 1, 2019
225.37 KRW
Jan 1, 2020
-759.33 KRW
Jan 1, 2021
-4,917.61 KRW
Jan 1, 2022
-3,294.58 KRW
Jan 1, 2023
-1,963.81 KRW
Jan 1, 2024
-658.01 KRW
Jan 1, 2025
284.06 KRW
The GeneSystem Co Net Debt per Share history
YEARNet Debt per ShareYoY
284.06KRW-143.17%
-658.01KRW-66.49%
-1,963.81KRW-40.39%
-3,294.58KRW-33.00%
-4,917.61KRW+547.62%
-759.33KRW-436.92%
225.37KRW+357.03%
49.31KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneSystem Co Stock analysis

What does GeneSystem Co do? GeneSystem Co., Ltd generates revenue through the development, manufacturing, and sale of PCR-based molecular diagnostic products. The company offers molecular diagnosis systems, biochips, test kits, and reaction reagents, targeting healthcare providers and laboratories seeking advanced in vitro diagnostic solutions. Its core business focuses on molecular diagnosis technology, complementing immunodiagnosis technology to deliver comprehensive diagnostic tools. The firm serves medical institutions requiring precise and efficient diagnostic equipment for disease detection and monitoring. The company's product portfolio includes platform-based molecular diagnostic systems, biochips, and test kits designed for laboratory use. These products are sold directly to healthcare facilities and diagnostic laboratories, supporting applications in infectious disease testing and genetic analysis. By leveraging its expertise in molecular diagnosis, GeneSystem Co., Ltd provides essential tools for medical professionals to enhance diagnostic accuracy and patient care. GeneSystem Co., Ltd's revenue streams are derived from the sale of diagnostic systems, biochips, and consumables such as test kits and reaction reagents. The firm's target market comprises healthcare institutions and laboratories that require reliable in vitro diagnostic technology. The company's focus on molecular diagnosis technology positions it as a key supplier in the diagnostic equipment sector, meeting the growing demand for advanced diagnostic solutions in healthcare. GeneSystem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneSystem Co stock

Net Debt per Share of GeneSystem Co is 284.06 KRW in 2025.

Net Debt per Share of GeneSystem Co changed from -658.01 KRW to 284.06 KRW, representing a -143.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share GeneSystem Co since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — GeneSystem Co

All Key Metrics — GeneSystem Co